Drug-induced acute pancreatitis: Results from the hospital-based Berlin case-control surveillance study of 102 cases

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 825-834

  Douros, A ^a   Bronder, E ^a   Andersohn, F ^a   Klimpel, A ^a   Thomae, M ^b   Ockenga, J ^c   Kreutz, R ^a   Garbe, E ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Abteilung Innere Medizin Gastroenterologie   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

^d LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; AZATHIOPRINE; BISOPROLOL; BUDESONIDE PLUS FORMOTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESOMEPRAZOLE; FENOFIBRATE; FUROSEMIDE; HARPAGOPHYTUM EXTRACT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS RAMIPRIL; LEFLUNOMIDE; LISINOPRIL; MERCAPTOPURINE; MESALAZINE; METFORMIN; METOPROLOL; NEBIVOLOL; OMEPRAZOLE; PANTOPRAZOLE; RAMIPRIL; SIMVASTATIN; TIMOLOL; TOCILIZUMAB; TORASEMIDE; UNINDEXED DRUG; VALERIAN;

ACUTE PANCREATITIS; ADULT; ARTICLE; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

ADULT; AGED; BERLIN; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATITIS; PHYTOTHERAPY; RISK;

EID: 84883467005     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12461     Document Type: Article

References (49)

1. Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J,. Drug-induced pancreatitis. Curr Gastroenterol Rep 2012; 14: 131-8.
2. Bergholm U, Langman M, Rawllins M, et al,. Drug-induced acute pancreatitis, Pharmacoepidemiol Drug Saf 1995; 4: 329-34.
3. Garbe E, Suissa S,. Pharmacoepidemiology. In:, Ahrens W, Pigeot I, eds. Handbook of Epidemiology. Berlin: Springer Verlag, 2005; 1225-66.
4. Andersohn F, Bronder E, Klimpel A, Garbe E,. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin case-control surveillance study. Am J Hematol 2004; 77: 316-8.
5. Garbe E, Andersohn F, Bronder E, et al,. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011; 154: 644-53.
6. Garbe E, Andersohn F, Bronder E, et al,. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2012; 68: 821-32.
7. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS,. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992; 135: 1029-41.
8. Grimes DA, Schulz KF,. Compared to what? Finding controls for case-control studies. Lancet 2005; 365: 1429-33.
9. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Available at: http://who-umc.org/ Graphics/24734.pdf. 2012. Accessed February 24, 2012.
10. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). Available at: http://www.who.int/classifications/atcddd/ en/. 2003. Accessed February 24, 2012.
11. Lancashire RJ, Cheng K, Langman MJ,. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther 2003; 17: 887-93.
12. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT,. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol 2003; 98: 1305-8.
13. van Geenen EJ, de Boer NK, Stassen P, et al,. Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon. Aliment Pharmacol Ther 2010; 31: 1322-9.
14. Eland IA, Sundstrom A, Velo GP, et al,. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol 2006; 41: 1484-90.
15. Enger C, Gately R, Ming EE, Niemcryk SJ, Williams L, McAfee AT,. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010; 106: 1594-601.
16. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P,. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004; 31: 1906-11.
17. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH,. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999; 94: 2417-22.
18. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S,. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5: 648-61.
19. Trivedi CD, Pitchumoni CS,. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709-16.
20. Bermejo F, Lopez-Sanroman A, Taxonera C, et al,. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008; 28: 623-8.
21. Munk EM, Pedersen L, Floyd A, Norgard B, Rasmussen HH, Sorensen HT,. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004; 99: 884-8.
22. Preiss D, Tikkanen MJ, Welsh P, et al,. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308: 804-11.
23. Famularo G, Polchi S, De SC,. Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int 1999; 14: 202-4.
24. Maranan MC, Gerber SI, Miller GG,. Gallstone pancreatitis caused by ceftriaxone. Pediatr Infect Dis J 1998; 17: 662-3.
25. Ruggiero S, DI Nardo R, Polimeno T, Rossi F, Capuano A,. Ceftriaxone-induced pancreatitis in a pediatric patient: case report. J Chemother 2010; 22: 63-5.
26. Sasaki Y, Aoki S, Aoki K, et al,. Acute pancreatitis associated with the administration of ceftriaxone in an adult patient. Nihon Shokakibyo Gakkai Zasshi 2009; 106: 569-75.
27. Zimmermann AE, Katona BG, Jodhka JS, Williams RB,. Ceftriaxone-induced acute pancreatitis. Ann Pharmacother 1993; 27: 36-7.
28. Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ,. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991; 86: 1251-4.
29. Grant L, McBean DE, Fyfe L, Warnock AM,. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res 2007; 21: 199-209.
30. Stevinson C, Ernst E,. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000; 1: 91-9.
31. Miyagoshi M, Amagaya S, Ogihara Y,. Choleretic actions of iridoid compounds. J Pharmacobiodyn 1988; 11: 186-90.
32. Devil's claw-Product information. Available at: http://www.nlm.nih.gov/ medlineplus/druginfo/natural/984.html?print=y. 2012. Accessed November 20, 2012.
33. Cohen DL, Del TY,. A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 2008; 42: 961-2.
34. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC,. Hepatotoxicity of herbal remedies. BMJ 1989; 299: 1156-7.
35. Vassiliadis T, Anagnostis P, Patsiaoura K, et al,. Valeriana hepatotoxicity. Sleep Med 2009; 10: 935.
36. Bruminhent J, Carrera P, Li Z, Amankona R, Roberts IM,. Acute pancreatitis with saw palmetto use: a case report. J Med Case Rep 2011; 5: 414.
37. Jibrin I, Erinle A, Saidi A, Aliyu ZY,. Saw palmetto-induced pancreatitis. South Med J 2006; 99: 611-2.
38. Lesser D, Hillesheim P,. Pancreatitis in a woman taking an herbal supplement. South Med J 2007; 100: 59-60.
39. Varvarelis N, Khallafi H, Pappachen B, Krishnamurthy M,. Natural therapies-when ignorance is not bliss!!. J Am Geriatr Soc 2007; 55: 1892-3.
40. Wargo KA, Allman E, Ibrahim F,. A possible case of saw palmetto-induced pancreatitis. South Med J 2010; 103: 683-5.
41. Lindkvist B, Appelros S, Manjer J, Berglund G, Borgstrom A,. A prospective cohort study of smoking in acute pancreatitis. Pancreatology 2008; 8: 63-70.
42. Noel RA, Braun DK, Patterson RE, Bloomgren GL,. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-8.
43. Eland IA, Rasch MC, Sturkenboom MJ, et al,. Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology 2000; 119: 230-3.
44. Tosun E, Oksuzoglu B, Topaloglu O,. Relationship between acute pancreatitis and ACE inhibitors. Acta Cardiol 2004; 59: 571-2.
45. Lee JK, Enns R,. Review of idiopathic pancreatitis. World J Gastroenterol 2007; 13: 6296-313.
46. Sundstrom A, Blomgren K, Alfredsson L, Wiholm BE,. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis-results from a Swedish Case-Control Study. Pharmacoepidemiol Drug Saf 2006; 15: 141-9.
47. Mesalazine-German prescribing information. Available at: http://www.fachinfo.de/viewFI?FINR=007706,007708&RL= Salofalk%26reg%3B%20250%26nbsp%3Bmg/- 500%26nbsp%3Bmg%20magensaftresistente%20Tabletten. 2012. Accessed July 4, 2013.
48. Lipworth BJ,. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
49. Nelp WB,. Acute pancreatitis associated with steroid therapy. Arch Intern Med 1961; 108: 702-10.